Clinical Trial Update: Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4 [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating extending treatment to 24 weeks in HIV-Hepatitis C co-infected patients (genotypes 1 and/or 4), with outcomes on efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hepatitis C

Snippet

Sponsor: Hospital Clinico Universitario San Cecilio | Conditions: HIV Infections, Hepatitis C | Phase 4 | Status: COMPLETED